Graham Peigh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Graham Peigh has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Rod Passman
Division of Cardiology, Feinberg School of Medicine, Northwestern University , 676 N St Claire, Suite 600, Chicago, IL 60611
13 shared publications - Bradley P. Knight
Feinberg School of Medicine, Division of Cardiology Northwestern University Chicago Illinois USA
9 shared publications Albert Lin
Clinical Cardiac Electrophysiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
5 shared publicationsAlexandru B. Chicos
Division of Cardiology Northwestern University, Feinberg School of Medicine Chicago Illinois USA
4 shared publicationsAmar Trivedi
Medical Center of the Rockies, Loveland, Colorado, USA
4 shared publicationsBradley P. Knight
Department of Medicine (Cardiology) Northwestern University Feinberg School of Medicine Chicago Illinois USA
4 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Safety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry
Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.
- 25 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessSafety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry
Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.
- Open Access
- 10 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Cardiac Implantable Electronic Device Infection: Nationwide Trends in Extraction Utilization and In‐Hospital Outcomes
Introduction: Contemporary, real‐world adherence to guideline‐directed transvenous cardiac implantable electronic device (CIED) extraction for patients with CIED infections in the US remains incompletely characterized. As such, we sought to evaluate national trends in CIED extraction and identify factors associated with extraction and in‐hospital mortality. Methods: A retrospective analysis of adult hospitalizations with CIED infection using the National Inpatient Sample from 2016 to 2022 was performed. National trends in extraction, factors associated with extraction, and predictors of in‐hospital mortality were evaluated. Multivariable logistic regression and propensity score matching were used to estimate adjusted associations with mortality. Results: Among 47,835 adults hospitalized with a CIED infection, 10,905 (22.8%) underwent extraction. National extraction rates increased modestly from 16.2% in 2016 to 23.8% in 2022 ( p < 0.001) but remained low overall. Unadjusted in‐hospital mortality was lower among patients who underwent extraction compared with those who did not (2.8% vs. 4.4%; p = 0.001). After adjustment, extraction was independently associated with lower mortality (OR 0.59 [95% CI, 0.44–0.80]). Higher mortality was associated with increasing age, greater comorbidity burden, and markers of acute illness severity, including acute kidney injury, cardiogenic shock, and respiratory failure. Among patients who underwent extraction, markers of acute organ failure remained associated with adjusted in‐hospital mortality. Conclusions: In this contemporary, multi‐payor, national cohort of patients with CIED infections, CIED extraction was independently associated with lower in‐hospital mortality, but was significantly underutilized despite guideline recommendations. Mortality among those who underwent extraction was driven primarily by acute illness severity, emphasizing the need for early recognition and timely intervention. System‐level strategies to improve access to extraction may help align real‐world practice with guidelines.
- 10 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Open AccessCardiac Implantable Electronic Device Infection: Nationwide Trends in Extraction Utilization and In‐Hospital Outcomes
Introduction: Contemporary, real‐world adherence to guideline‐directed transvenous cardiac implantable electronic device (CIED) extraction for patients with CIED infections in the US remains incompletely characterized. As such, we sought to evaluate national trends in CIED extraction and identify factors associated with extraction and in‐hospital mortality. Methods: A retrospective analysis of adult hospitalizations with CIED infection using the National Inpatient Sample from 2016 to 2022 was performed. National trends in extraction, factors associated with extraction, and predictors of in‐hospital mortality were evaluated. Multivariable logistic regression and propensity score matching were used to estimate adjusted associations with mortality. Results: Among 47,835 adults hospitalized with a CIED infection, 10,905 (22.8%) underwent extraction. National extraction rates increased modestly from 16.2% in 2016 to 23.8% in 2022 ( p < 0.001) but remained low overall. Unadjusted in‐hospital mortality was lower among patients who underwent extraction compared with those who did not (2.8% vs. 4.4%; p = 0.001). After adjustment, extraction was independently associated with lower mortality (OR 0.59 [95% CI, 0.44–0.80]). Higher mortality was associated with increasing age, greater comorbidity burden, and markers of acute illness severity, including acute kidney injury, cardiogenic shock, and respiratory failure. Among patients who underwent extraction, markers of acute organ failure remained associated with adjusted in‐hospital mortality. Conclusions: In this contemporary, multi‐payor, national cohort of patients with CIED infections, CIED extraction was independently associated with lower in‐hospital mortality, but was significantly underutilized despite guideline recommendations. Mortality among those who underwent extraction was driven primarily by acute illness severity, emphasizing the need for early recognition and timely intervention. System‐level strategies to improve access to extraction may help align real‐world practice with guidelines.
- Open Access
- 10 July 2026
- Published by Elsevier in JACC: Case Reports
- p. 109094
Secondary Cardiac Lymphoma Causing High-Grade Heart Block
- 10 July 2026
- Published by Elsevier in JACC: Case Reports
- p. 109094
Open AccessSecondary Cardiac Lymphoma Causing High-Grade Heart Block
- 14 March 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (5) , 1128-1130
Are Some Insertable Cardiac Monitors More Equal Than Others?
- 14 March 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (5) , 1128-1130
Are Some Insertable Cardiac Monitors More Equal Than Others?
- Open Access
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Postoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Open AccessPostoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- 1 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 3004-3006
Etripamil Nasal Spray to Keep the Doctor Away
- 1 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 3004-3006
Etripamil Nasal Spray to Keep the Doctor Away
- Open Access
- 28 July 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (14) , 1762-1772
Outcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement
- 28 July 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (14) , 1762-1772
Open AccessOutcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement
- 15 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (15) , e925
Response by Peigh et al to Letter Regarding Article, “Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices”
- 15 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (15) , e925
Response by Peigh et al to Letter Regarding Article, “Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices”
- Open Access
- 2 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2767-2775
Implantable Defibrillators: Which Is the Best Device for Each Patient?
The first viable alternative to surgical implantation of an epicardial defibrillator system for secondary prevention of sudden cardiac death (SCD) was a single chamber transvenous implantable cardioverter defibrillator (ICD). Thanks to technological advancements over the past 40 years, electrophysiologists now have several options when determining the optimal type of ICD to provide protection against SCD, including the number of leads implanted, whether a patient meets indications for cardiac resynchronization, and if the patient would benefit from an extravascular device. In this review, we will detail the breadth of options for commercially available ICD therapy to provide guidance on which device is best suited for specific patient populations.
- 2 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2767-2775
Open AccessImplantable Defibrillators: Which Is the Best Device for Each Patient?
The first viable alternative to surgical implantation of an epicardial defibrillator system for secondary prevention of sudden cardiac death (SCD) was a single chamber transvenous implantable cardioverter defibrillator (ICD). Thanks to technological advancements over the past 40 years, electrophysiologists now have several options when determining the optimal type of ICD to provide protection against SCD, including the number of leads implanted, whether a patient meets indications for cardiac resynchronization, and if the patient would benefit from an extravascular device. In this review, we will detail the breadth of options for commercially available ICD therapy to provide guidance on which device is best suited for specific patient populations.